We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Simulations Plus Inc (SLP) Com USD0.001

Sell:$25.38 Buy:$33.28 Change: $0.30 (1.04%)
NASDAQ:1.03%
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$25.38
Buy:$33.28
Change: $0.30 (1.04%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$25.38
Buy:$33.28
Change: $0.30 (1.04%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The Company’s comprehensive bio simulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. It operates through two segments: software and services. It offers software products for pharmaceutical research, development, and commercialization, including GastroPlus, DDDPlus, MembranePlus, ADMET Predictor, MedChem Designer, DILIsym, NAFLDsym, ILDsym, IPFsym and others. In addition, it also delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development.

Contact details

Address:
42505 10Th Street West
LANCASTER
93534-7059
United States
Telephone:
+1 (661) 7237723
Website:
https://www.simulations-plus.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SLP
ISIN:
US8292141053
Market cap:
$573.12 million
Shares in issue:
20.07 million
Sector:
Health Care Technology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Shawn O'Connor
    Chief Executive Officer
  • William Frederick
    Chief Financial Officer, Chief Operating Officer, Secretary
  • John Dibella
    President - PBPK, Regulatory Strategies, Cheminformatics Solutions
  • Jill Fiedler-Kelly
    President - Clinical Pharmacology and Pharmacometric Services
  • Michael Raymer
    President - Business Unit
  • Sandra Suarez Sharp
    President - Regulatory Strategies
  • Dan Szot
    Chief Revenue Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.